The move follows a Friday ruling by the 5th U.S. Circuit Court of Appeals that temporarily blocked deliveries of the drug, a decision that threatens to significantly curtail access to the most common abortion method in the U.S.
The legal battle centers on a 2023 FDA decision that lifted in-person dispensing requirements, a regulation the state of Louisiana successfully challenged by alleging the agency ignored potential health risks like sepsis and hemorrhaging.
Danco Laboratories, which produces the brand-name Mifeprex, warned that the current suspension "injects immediate confusion and upheaval" into time-sensitive medical decisions for providers and pharmacies alike.
Regulatory authority and market impact under scrutiny
The outcome of the Supreme Court petition carries heavy implications for the FDA’s regulatory autonomy and the pharmaceutical landscape.
Mifepristone is currently utilized in approximately two-thirds of all U.S. abortions, and for manufacturers like GenBioPro, the drug represents the vast majority of total revenue.
Proponents of the mail-order rule argue that the legal challenge is an attempt by special interests to undermine established evidence-based healthcare.
While the Trump administration has indicated it is reviewing the drug’s safety, reports suggest the results of that review may be delayed until after the November midterm elections.
The Supreme Court’s involvement marks the latest escalation in a series of legal conflicts following the 2022 overturning of Roe v. Wade, as nearly half of U.S. states have moved to ban or severely restrict abortion access.
The ongoing volatility continues to create a complex environment for healthcare providers and investors monitoring the intersection of law and pharmaceutical policy.
source https://www.investing.com/news/economy-news/drugmakers-petition-supreme-court-to-restore-mifepristone-mailorder-access-4654800
